{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T04:09:47Z","timestamp":1772683787192,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In this modern era of precision medicine, molecular signatures identified from advanced omics technologies hold great promise to better guide clinical decisions. However, current approaches are often location-specific due to the inherent differences between platforms and across multiple centres, thus limiting the transferability of molecular signatures. We present Cross-Platform Omics Prediction (CPOP), a penalised regression model that can use omics data to predict patient outcomes in a platform-independent manner and across time and experiments. CPOP improves on the traditional prediction framework of using gene-based features by selecting ratio-based features with similar estimated effect sizes. These components gave CPOP the ability to have a stable performance across datasets of similar biology, minimising the effect of technical noise often generated by omics platforms. We present a comprehensive evaluation using melanoma transcriptomics data to demonstrate its potential to be used as a critical part of a clinical screening framework for precision medicine. Additional assessment of generalisation was demonstrated with ovarian cancer and inflammatory bowel disease studies.<\/jats:p>","DOI":"10.1038\/s41746-022-00618-5","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T04:03:18Z","timestamp":1656907398000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cross-Platform Omics Prediction procedure: a statistical machine learning framework for wider implementation of precision medicine"],"prefix":"10.1038","volume":"5","author":[{"given":"Kevin Y. X.","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulietta M.","family":"Pupo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varsha","family":"Tembe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellis","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Strbenac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah-Jane","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8991-0013","authenticated-orcid":false,"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3087-8127","authenticated-orcid":false,"given":"Samuel","family":"Muller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6605-7478","authenticated-orcid":false,"given":"Garth","family":"Tarr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham J.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-2603","authenticated-orcid":false,"given":"Jean Y. H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"618_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2019.10.027","volume":"125","author":"TMS Amaral","year":"2020","unstructured":"Amaral, T. M. S. et al. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. Eur. J. Cancer 125, 38\u201345 (2020).","journal-title":"Eur. J. Cancer"},{"key":"618_CR2","doi-asserted-by":"crossref","unstructured":"Diefenbach, R. J. et al. Design and testing of a custom melanoma next generation sequencing panel for analysis of circulating tumor DNA. Cancers 12, 2228. https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2228 (2020).","DOI":"10.3390\/cancers12082228"},{"key":"618_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaad.2020.03.053","volume":"83","author":"BN Greenhaw","year":"2020","unstructured":"Greenhaw, B. N. et al. Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. J. Am. Acad. Dermatol. 83, 745\u2013753 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"618_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2020.10.016","volume":"143","author":"T Gambichler","year":"2021","unstructured":"Gambichler, T. et al. Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients. Eur. J. Cancer 143, 11\u201318 (2021).","journal-title":"Eur. J. Cancer"},{"key":"618_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21207-2","volume":"12","author":"M Garg","year":"2021","unstructured":"Garg, M. et al. Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nat. Commun. 12, 1137 (2021).","journal-title":"Nat. Commun."},{"key":"618_CR6","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s40257-019-00464-4","volume":"20","author":"DP Dubin","year":"2019","unstructured":"Dubin, D. P., Dinehart, S. M. & Farberg, A. S. Level of evidence review for a gene expression profile test for cutaneous melanoma. Am. J. Clin. Dermatol. 20, 763\u2013770 (2019).","journal-title":"Am. J. Clin. Dermatol."},{"key":"618_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/jid.2012.283","volume":"133","author":"GJ Mann","year":"2013","unstructured":"Mann, G. J. et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III Melanoma. J. Invest. Dermatol. 133, 509\u2013517 (2013).","journal-title":"J. Invest. Dermatol."},{"key":"618_CR8","doi-asserted-by":"publisher","unstructured":"Grossman, D. et al. Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1729 (2020).","DOI":"10.1001\/jamadermatol.2020.1729"},{"key":"618_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64212-z","volume":"10","author":"J Reinders","year":"2020","unstructured":"Reinders, J. et al. Platform independent protein-based cell-of-origin subtyping of diffuse large B-cell lymphoma in formalin-fixed paraffin-embedded tissue. Sci. Rep. 10, 7876 (2020). 12\/.","journal-title":"Sci. Rep."},{"key":"618_CR10","doi-asserted-by":"publisher","first-page":"i333","DOI":"10.1093\/bioinformatics\/btx241","volume":"33","author":"M Altenbuchinger","year":"2017","unstructured":"Altenbuchinger, M. et al. Molecular signatures that can be transferred across different omics platforms. Bioinformatics 33, i333\u2013i340 (2017).","journal-title":"Bioinformatics"},{"key":"618_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/bioinformatics\/btw598","volume":"33","author":"M Altenbuchinger","year":"2017","unstructured":"Altenbuchinger, M. et al. Reference point insensitive molecular data analysis. Bioinformatics 33, 219\u2013226 (2017).","journal-title":"Bioinformatics"},{"key":"618_CR12","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"The Cancer Genome Atlas Network.","year":"2015","unstructured":"The Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681\u20131696 (2015).","journal-title":"Cell"},{"key":"618_CR13","doi-asserted-by":"publisher","first-page":"12297","DOI":"10.18632\/oncotarget.3655","volume":"6","author":"H Cirenajwis","year":"2015","unstructured":"Cirenajwis, H. et al. Molecular stratification of metastatic melanoma using gene expression profiling: prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget 6, 12297\u201312309 (2015).","journal-title":"Oncotarget"},{"key":"618_CR14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/ijc.29047","volume":"136","author":"K Jayawardana","year":"2015","unstructured":"Jayawardana, K. et al. Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information. Int. J. Cancer 136, 863\u2013874 (2015).","journal-title":"Int. J. Cancer"},{"key":"618_CR15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. Regression shrinkage and selection via the Lasso. J. R. Stat. Soc. Ser. B Stat. Methodol. 58, 10\u201314 (1996).","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."},{"key":"618_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan, E. L. & Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457\u2013481 (1958).","journal-title":"J. Am. Stat. Assoc."},{"key":"618_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118\u2013127 (2007).","journal-title":"Biostatistics"},{"key":"618_CR18","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1038\/bjc.2013.557","volume":"109","author":"D Bedognetti","year":"2013","unstructured":"Bedognetti, D. et al. CXCR3\/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br. J. Cancer 109, 2412\u20132423 (2013).","journal-title":"Br. J. Cancer"},{"key":"618_CR19","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","volume":"69","author":"H Harlin","year":"2009","unstructured":"Harlin, H. et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69, 3077\u20133085 (2009).","journal-title":"Cancer Res"},{"key":"618_CR20","doi-asserted-by":"publisher","first-page":"29111","DOI":"10.18632\/oncotarget.5059","volume":"6","author":"T Barbai","year":"2015","unstructured":"Barbai, T., Fej\u0151s, Z., Puskas, L. G., T\u00edm\u00e1r, J. & R\u00e1s\u00f3, E. The importance of microenvironment: the role of CCL8 in metastasis formation of melanoma. Oncotarget 6, 29111\u201329128 (2015).","journal-title":"Oncotarget"},{"key":"618_CR21","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/j.ajpath.2019.06.010","volume":"189","author":"M Wagner","year":"2019","unstructured":"Wagner, M., Steinskog, E. S. & Wiig, H. Blockade of lymphangiogenesis shapes tumor-promoting adipose tissue inflammation. Am. J. Pathol. 189, 2102\u20132114 (2019).","journal-title":"Am. J. Pathol."},{"key":"618_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/CMR.0000000000000533","volume":"29","author":"D Strbenac","year":"2019","unstructured":"Strbenac, D. et al. Melanoma Explorer: a web application to allow easy reanalysis of publicly available and clinically annotated melanoma omics data sets. Melanoma Res 29, 342\u2013344 (2019).","journal-title":"Melanoma Res"},{"key":"618_CR23","doi-asserted-by":"crossref","unstructured":"Waldron, L. et al. Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. JNCI: J. of the Natl. Cancer Inst. 106, dju049. https:\/\/academic.oup.com\/jnci\/article\/106\/5\/dju049\/2606979 (2014).","DOI":"10.1093\/jnci\/dju049"},{"key":"618_CR24","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/1078-0432.CCR-11-2725","volume":"18","author":"K Yoshihara","year":"2012","unstructured":"Yoshihara, K. et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin. Cancer Res. 18, 1374\u20131385 (2012).","journal-title":"Clin. Cancer Res."},{"key":"618_CR25","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198\u20135208 (2008).","journal-title":"Clin. Cancer Res."},{"key":"618_CR26","first-page":"e87899","volume":"1","author":"JM Peloquin","year":"2016","unstructured":"Peloquin, J. M. et al. Characterization of candidate genes in inflammatory bowel disease - associated risk loci. J. Clin. Investig. Insight 1, e87899 (2016).","journal-title":"J. Clin. Investig. Insight"},{"key":"618_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/1741-7015-11-220","volume":"11","author":"LM McShane","year":"2013","unstructured":"McShane, L. M. et al. Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med 11, 220, https:\/\/doi.org\/10.1186\/1741-7015-11-220 (2013).","journal-title":"BMC Med"},{"key":"618_CR28","doi-asserted-by":"publisher","first-page":"561763","DOI":"10.3389\/fonc.2021.561763","volume":"11","author":"D Qin","year":"2021","unstructured":"Qin, D. et al. Predict colon cancer by pairing plasma miRNAs: establishment of a normalizer-free, cross-platform model. Front. Oncol. 11, 561763 (2021).","journal-title":"Front. Oncol."},{"key":"618_CR29","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0168-9525(03)00140-9","volume":"19","author":"E Eisenberg","year":"2003","unstructured":"Eisenberg, E. & Levanon, E. Y. Human housekeeping genes are compact. Trends Genet 19, 362\u2013365 (2003).","journal-title":"Trends Genet"},{"key":"618_CR30","unstructured":"R Core Team. R: A language and environment for statistical computing. (2019)."},{"key":"618_CR31","unstructured":"Nickles, D., Sandmann, T., Ziman, R. & Bourgon, R. NanoStringQCPro: Quality metrics and data processing methods for NanoString mRNA gene expression data. https:\/\/www.bioconductor.org\/packages\/release\/bioc\/html\/NanoStringQCPro.html (2017)."},{"key":"618_CR32","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47 (2015).","journal-title":"Nucleic Acids Res"},{"key":"618_CR33","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1093\/bioinformatics\/btv066","volume":"31","author":"D Strbenac","year":"2015","unstructured":"Strbenac, D., Mann, G. J., Ormerod, J. T. & Yang, J. Y. H. ClassifyR: an R package for performance assessment of classification with applications to transcriptomics. Bioinformatics 31, 1851\u20131853 (2015).","journal-title":"Bioinformatics"},{"key":"618_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1\u201322 (2010).","journal-title":"J. Stat. Softw."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00618-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00618-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00618-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T07:21:51Z","timestamp":1727508111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00618-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["618"],"URL":"https:\/\/doi.org\/10.1038\/s41746-022-00618-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.12.09.415927","asserted-by":"object"}]},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"assertion":[{"value":"10 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.A.S. has received fees for professional services from F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, MSD Sharp & Dohme, NeraCare, AMGEN., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline. J.F.T. has received honoraria for advisory board participation from BMS Australia, MSD Australia, GlaxoSmithKline and Provectus Inc, and travel support from GlaxoSmithKline and Provectus Inc. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}